Zevra Therapeutics (ZVRA) EBT (2014 - 2026)
Zevra Therapeutics (ZVRA) reported EBT of $44.8 million for Q1 2026, up 2437.19% on a YoY basis from $1.8 million in Q1 2025, and up 253.73% quarter-over-quarter from $12.7 million in Q4 2025.
Zevra Therapeutics (ZVRA) EBT (2014 - 2026) Analysis & Trends
Zevra Therapeutics has reported EBT for 13 years, with the latest figure at $44.8 million in Q1 2026.
- For the quarter ending Q1 2026, EBT rose 2437.19% year-over-year to $44.8 million; the trailing twelve-month figure through Mar 2026 stood at $133.4 million (up 277.0% YoY), and the FY2025 full-year result was $86.7 million, up 196.16% from the prior year.
- EBT for Q1 2026 stood at $44.8 million, up from $12.7 million in the prior quarter.
- The five-year high for EBT was $76.9 million in Q2 2025, with the low at -$36.3 million in Q4 2022.
- Historically, EBT has averaged -$3.4 million across 5 years, with a median of -$10.2 million in 2023.
- Annual changes were most pronounced in 2022 — EBT tumbled 1270.09% — and 2026, when it soared 2437.19%.
- Zevra Therapeutics' EBT stood at -$36.3 million in 2022, then soared by 45.17% to -$19.9 million in 2023, then fell by 2.39% to -$20.4 million in 2024, then soared by 162.19% to $12.7 million in 2025, then soared by 253.73% to $44.8 million in 2026.
- The last three EBT figures came in at $44.8 million (Q1 2026), $12.7 million (Q4 2025), and -$977000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -15.31 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.18 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Zevra Therapeutics | 704.96 Mn | 504.34 Mn | 34.30 Mn | 44.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.80 Mn |
| Dec 31, 2025 | 12.67 Mn |
| Sep 30, 2025 | -977,000.00 |
| Jun 30, 2025 | 76.91 Mn |
| Mar 31, 2025 | -1.92 Mn |
| Dec 31, 2024 | -20.37 Mn |
| Sep 30, 2024 | -33.23 Mn |
| Jun 30, 2024 | -19.86 Mn |
| Mar 31, 2024 | -16.69 Mn |
| Dec 31, 2023 | -19.89 Mn |
| Sep 30, 2023 | -10.19 Mn |
| Jun 30, 2023 | -2.65 Mn |
| Mar 31, 2023 | -13.32 Mn |
| Dec 31, 2022 | -36.28 Mn |
| Sep 30, 2022 | -5.70 Mn |
| Jun 30, 2022 | -21.93 Mn |
| Mar 31, 2022 | 10.48 Mn |
| Dec 31, 2021 | -2.65 Mn |
| Sep 30, 2021 | -1.76 Mn |
| Jun 30, 2021 | 6.20 Mn |